252 related articles for article (PubMed ID: 23360797)
41. Expression of 67-kDa laminin receptor was associated with tumor progression and poor prognosis in epithelial ovarian cancer.
Song T; Choi CH; Cho YJ; Sung CO; Song SY; Kim TJ; Bae DS; Lee JW; Kim BG
Gynecol Oncol; 2012 May; 125(2):427-32. PubMed ID: 22285843
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.
Ying X; Wei K; Lin Z; Cui Y; Ding J; Chen Y; Xu B
Cell Physiol Biochem; 2016; 39(2):501-10. PubMed ID: 27383536
[TBL] [Abstract][Full Text] [Related]
43. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
45. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
[TBL] [Abstract][Full Text] [Related]
46. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
47. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
[TBL] [Abstract][Full Text] [Related]
48. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
49. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
[TBL] [Abstract][Full Text] [Related]
50. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
51. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
52. lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2.
Zeng XY; Jiang XY; Yong JH; Xie H; Yuan J; Zeng D; Dou YY; Xiao SS
Cancer Med; 2019 Nov; 8(16):7074-7085. PubMed ID: 31568657
[TBL] [Abstract][Full Text] [Related]
53. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract][Full Text] [Related]
54. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
55. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4.
Lin J; Zhang L; Huang H; Huang Y; Huang L; Wang J; Huang S; He L; Zhou Y; Jia W; Yun J; Luo R; Zheng M
Oncotarget; 2015 Sep; 6(27):23793-806. PubMed ID: 26204489
[TBL] [Abstract][Full Text] [Related]
56. The role of Cyclin G1 in cellular proliferation and apoptosis of human epithelial ovarian cancer.
Jiang L; Liu R; Wang Y; Li C; Xi Q; Zhong J; Liu J; Yang S; Wang J; Huang M; Tang C; Fang Z
J Mol Histol; 2015 Jun; 46(3):291-302. PubMed ID: 25981880
[TBL] [Abstract][Full Text] [Related]
57. The role of S100A14 in epithelial ovarian tumors.
Cho H; Shin HY; Kim S; Kim JS; Chung JY; Chung EJ; Chun KH; Hewitt SM; Kim JH
Oncotarget; 2014 Jun; 5(11):3482-96. PubMed ID: 24939856
[TBL] [Abstract][Full Text] [Related]
58. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
59. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
60. The lymphotactin receptor is expressed in epithelial ovarian carcinoma and contributes to cell migration and proliferation.
Kim M; Rooper L; Xie J; Rayahin J; Burdette JE; Kajdacsy-Balla AA; Barbolina MV
Mol Cancer Res; 2012 Nov; 10(11):1419-29. PubMed ID: 22964431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
